Breast Cancer is the second leading cause of mortality in women in the United States. Breast cancer arise in the ducts of the mammary glands that produces milk in a lactating breast. Breast cancers usually express various proteins called hormone receptors for hormones like estrogen and progesterone. Some breast cancer cells also express a protein called Her2. Not all breast cancers express all the receptors and breast cancers can be divided into subcategories based on the expression of receptors. This is important for diagnosis as well as treatment as the receptors can be targeted with drugs as part of the treatment. However, certain breast cancer type do not express any of the previously mentioned receptors. This type of cancer is called Triple-negative breast cancer (TNBC). The treatment for TNBCs is mostly dependent on standard chemotherapy. TNBC is also the most aggressive type of breast cancer as well. Thus TNCB type cancer can metastasize to other organs of the body, which results in death of the patients. Hence, there is urgency in developing new or novel therapeutic strategies for treatment of TNBC.

Fig. 1. Model of MCP-1 action in breast cancer cells. TNBC cells show higher expression of MCP-1 and can therefore be affected by MCP-1. Upregulation of MCP-1 activates a protein kinase called MAP kinase via activation of the MCP-1 specific receptor on the breast cancer cell surface. Thus, breast cancer cells expressing higher levels of MCP-1 tend to be more invasive and metastatic.

There is also significant amount of health disparity in breast cancer. Breast cancer incidence rates among women are comparable between European American and African Americans. However, the mortality rate among African-American patients are higher. Along with that, TNBC also affects African American women disproportionately at a younger age. However, the biological factors underscoring this disparity is still elusive.

Our study shows that a small secreted protein called Monocyte Chemoattractant Protein-1 (MCP-1) is a marker associated with TNBC and may play a key role in TNBC disease progression. We measure secreted MCP-1 by quantifying protein and also with mRNA levels which were determined by Real-time PCR in multiple breast cancer cell lines. The cell lines represents various breast cancer subtypes based on Estrogen, Progesterone or Her2 receptor protein expression. Our data show that MCP-1 is upregulated in TNBC cell lines both transcriptionally as well as in secreted protein levels compared to ER-positive luminal cell line, MCF-7. Breast cancer patients, with highly aggressive Basal or Claudin-low subtypes, also showed higher expression of MCP-1. We showed that treatment with MCP-1 induced cell invasion in various breast cancer cell types, without affecting cell proliferation. Small molecule inhibitor against Chemokine Receptor 2 (CCR2), the receptor for MCP-1 as well as inhibitor for an enzyme called MAP kinase negatively affected MCP-1 induced MCF-7 cell invasion. This suggests that MCP-1-CCR2 axis may regulate invasiveness via the MAP Kinase pathway. Knocking down MCP-1 decreased cell invasion in TNBC cell line, along with downregulation of key epithelial to mesenchymal transition markers which are important for cellular oncogenesis. Our study suggests that MCP-1 mediated pathways could be potential therapeutic targets for the treatment of TNBC and could reduce cancer health disparities.

Jay Vadgama
Division of Cancer Research and Training, Department of Medicine,
Charles R. Drew University of Medicine and Science,
Los Angeles, CA, 90059, USA

Publication

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV
Breast Cancer Res Treat. 2018 Aug

Read offline:     

Related Articles:

	Adopting mammary development gameplay in breast… The process by which the breast changes during puberty and lactation is incredibly unique. Those changes are essential for the functional mammary gland. These changes are triggered and orchestrated by…
	Chemokines, an answer to the gut inflammation? Our gut is a complex organ which not only digests the food but also acts as an immune organ. The gut is lined by a single layer of specialized cells…
	Structure and function of the esophageal mucosa Structure and function go hand-in-hand amongst the morphology, morphometry, biomechanics and secretory potential within the alimentary tract mucosa, submucosa and muscularis propria.  Structure must evolve first during the development of…
	Tissue-specific MED1 LxxLL motifs play critical… Estrogen Receptor (ER)  is a nuclear hormone receptor that plays important roles in normal mammary gland development as well as breast cancer growth and metastases. In a breast cancer setting,…
	Modeling mammary gland development: understanding… The mammary gland is an organ that develops almost completely after birth. It has been extensively studied and its development is well-characterized. As such, it provides an excellent model system…
	The mechanisms of MCP-1 production in tumor… When you look at tumors, you may think they are composed of 100% tumor cells. The fact is that tumor tissues contain not only tumor cells but also a variety…